While early reports (1 ,2 ) showed an association of the serologically defined HLA-DR4 and -DR1 spec ificities with rheumatoid arthritis (RA), more recent case-control studies show that this disease is associ ated with HLA-DRB 1 alleles encoding a short structural m otif in the third hyper variable region, the " shared epitope" (SE). This shared epitope may be encoded by any of three highly homologous amino acid sequences at positions 67 to 74 of this molecule: LLEQKRAA, LLEQRRAA or LLERR RAA (single letter amino acid code: A = alanine, E = glutamic acid, K = lysine, L = leucine, Q = glutamine, R = arginine) (3, 4) .
While case control studies in the general popula tion help to define the association between DRB1 alleles and disease susceptibility, data from diverse sources are needed to describe the genetic model for a given disease, e.g. mode of inheritance, the num ber of genes involved or the relative contribution of HLA to genetic predisposition. Twin studies, assess ing the frequency of disease concordance in monoand dizygotic twins, are very informative in this re spect (5) (6) (7) (8) (9) . k In RA, among the twin studies performed, the Finnish twin cohort study (6, 7) is unique in one as pect: By linking the Finnish twin cohort with the Sickness Insurance Register nearly all relevant twins are included in the study, resulting in virtually complete ascertainment. In such a study the risk o f bias is reduced, e.g. concordant twin pairs are not more likely to enter the study than discordant pairs. Avoiding these biases is important when differenti ating between several genetic models. Since in RA these genetic models have to incorporate the effects of HLA-DRB 1 alleles on RA risk, we perform ed HLA-DRB 1 typing of the Finnish monozygotic concordant affected twins.
From 4137 monozygotic twin pairs, in total eight monozygotic twin pairs, both individuals fulfilling the 1987 criteria of the American College of Rheu matology for RA, were identified (6, 7). The sam pling procedure, zygosity testing and clinical char acteristics of these twins have been described else where (6, 7). All 16 twin members were seroposi tive at some stage, 14 had erosive disease, 12 had been treated with gold and 7 had rheum atoid nod ules. Peripheral blood was available from all indi viduals except patient 1A and 8B.
For HLA-typing DNA was isolated from periph eral blood, amplified in a polymerase chain reaction (PCR) using primers PI and P2 specific for exon 2 (10), and screened using sequence specific (SSO) probes 1003 and 2810 described in the 11th w ork shop (11) , probes 88-144, 88-148, 88-150, 88-151, de Vries et al 6), Pair #7 did not meet the ACR criteria and is left out of this analysis. b Rheumatoid factor positivity in some phase of disease (Latex and/or Waaler-Rose; see ref (7)) 88-153, 89-55, 89-61 and 89-62 (10, 12) and probes 3, 4, 5, 6,10,11, 20, 21, 22 and 23 (13) . Sub typing of the HLA-DR4 associated alleles was per formed using primers 336C and 337C, and SSO probes 152B, 153B, 156C, 157C, 315B, 769C, GT86 (14), probe 10 (13) and probe 102G with the sequence 5'-AGAGGAGTCCGTGCGCT-3' (Gen erously provided by JSS Lanchbury, London). In every screening procedure, SSO probes were endlabelled using T4-kinase (15) , hybridized to the dotblotted PCR product, stringency washed using TMAC1 (16) , and detected by autoradiography. PCR-amplified DNA of homozygous typing cells from the Tenth International Histocompatibility Workshop was processed together with the samples to ascertain specific hybridization. Table 1 shows the typing results of the eight monozygotic concordant affected twin pairs. When blood was available from both twins typing results were identical within twin pairs; results are there fore not separately presented. Of the eight twin pairs six were HLA-DR4 positive, while in all at least one HLA-DRB I allele encoded the shared epitope. Two twin pairs were homozygous for HLA-DR4, while in four pairs both HLA-DRB 1 alleles encoded the shared epitope. All individuals with rheumatoid nodules encoded the shared epitope amino acid sequence LLEQRRAA (DRB 1*0404 or DRB1* 0101); no other associations of typing results with clinical features were observed.
To date, no HLA-DRB 1 typing data on Finnish RA patients are available; therefore typing results from a recent Dutch case-control study were used for reference. Compared to Dutch RA patients (17) the concordant monozygotic twins showed a signifi cantly higher allele frequency of the shared epitope (12/16 vj 159/334; Odd's Ratio OR=4.72; confi dence interval CI=1.70-13.10; Fisher exact P=0.004), while the higher frequencies of HLA-DR4 (OR=2.15; P=0.17), of homozygosity for HLA-DR4 (OR=2.60; P=0.25) and of homozygosity for SE (OR=3.28; P=0.10) did not reach signifi cance.
If homozygosity and heterozygosity for SE en code identical RA risks, the ratio between SE ho mozygous and heterozygous individuals should be identical in these monozygotic twin pairs and healthy controls. However, 4 in 8 monozygotic twins were homozygous for SE, while 13 in 73 SEpositive healthy controls were homozygous (OR=4.63; CI=1.02-20.89; P=0.05), thus support ing the concept that homozygosity for SE is associ ated with a higher RA risk.
Jawaheer et al. (9) reported earlier that concor dance in monozygotic twins is rare in the absence of the shared epitope. Our study confirms these find ings. Furthermore, it shows an increased frequency of homozygosity for the shared epitope alleles among these twins compared to normal controls, implicating a role for homozygosity in susceptibility to RA, in agreement with the HLA typing results in the UK nationwide RA twin study. This indicates that a genetic model for RA must include the effects of homozygosity. Combining the data presented here with HLA typing data and epidemiological data from other sources may help to clarify the role of HLA alleles in the genetic predisposition to RA.
